AstraZeneca defends the safety of its anti-covid vaccine: “No evidence of aggravated risk” of blood clot

“In fact, the numbers on this guy [de problème médical] are much lower in those who are vaccinated compared to what would be expected in the population as a whole, “the group added in a statement.

Denmark, Iceland and Norway announced Thursday the suspension of AstraZeneca vaccine injections, citing the principle of “precaution”. Bulgaria followed suit on Friday and Thailand delayed its campaign.

The WHO for its part said on Friday that there was “no reason not to use” AstraZeneca’s Covid vaccine.

A WHO spokesperson stressed that experts from that organization were looking at the information of blood clots, but noted that so far no cause and effect link had been found.

She also recalled that as of March 9, more than 268 million doses of Covid vaccines had been administered worldwide since the start of the pandemic, based on figures obtained by the WHO from the authorities. of each country. “No deaths have been linked to the administration of vaccines against Covid-19 until this date,” said the spokesperson.

This vaccine is the only one approved by the WHO with that of Pfizer-BioNTech, which is based on another technique.

“The benefits of the vaccine continue to outweigh its risks and the vaccine can continue to be administered while the investigation of cases of thromboembolism is underway,” for its part said Thursday evening the safety committee of the European Medicines Agency.

Earlier today, the Danish National Health Agency, the first to announce a suspension decision, had called for caution in the face of “serious cases of blood clots in vaccinated people”, although “in At present “no link between the vaccine and blood clots has been established.

Earlier this week, Austria stopped administering a batch of these vaccines after the death of a 49-year-old nurse from “serious bleeding disorders” a few days after being vaccinated.

Website design By BotEap.com

Add a Comment

Your email address will not be published. Required fields are marked *